Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Neuropsychopharmacology

• Publication date

  2016-02-18

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/npp.2016.27PMID 26888056PMCID PMC4946059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential Control of Cocaine Self-Administration by GABAergic and Glutamatergic CB1 Cannabinoid Receptors

  2016cited by this paper
• The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys.

  2015cited by this paper
• Cannabinoid abuse and addiction: Clinical and preclinical findings

  2015cited by this paper
• Medicinal chemistry of cannabinoids

  2015cited by this paper
• CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats

  2014cited by this paper
• Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid

  2013cited by this paper
• Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity

  2013cited by this paper
• Cannabinoid Discrimination and Antagonism by CB1 Neutral and Inverse Agonist Antagonists

  2013cited by this paper
• The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine‐induced dopamine elevations in the nucleus accumbens shell in rats

  2012cited by this paper
• Cannabinoid type 1 receptor antagonists for smoking cessation.

  2011cited by this paper
• Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats

  2011cited by this paper
• Nicotine receptor partial agonists for smoking cessation.

  2011cited by this paper
• The Endogenous Cannabinoid 2-Arachidonoylglycerol Is Intravenously Self-Administered by Squirrel Monkeys

  2011cited by this paper
• The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats.

  2010cited by this paper
• Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

  2010cited by this paper
• Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice

  2010cited by this paper
• Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB1 receptor blockade

  2009cited by this paper
• Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

  2009cited by this paper
• Effects of nicotine in experimental animals and humans: an update on addictive properties.

  2009cited by this paper
• The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse.

  2009cited by this paper
• Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

  2009cited by this paper
• Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113.

  2009cited by this paper
• Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.

  2008cited by this paper
• The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats.

  2008cited by this paper
• Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

  2008cited by this paper
• Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior

  2008cited by this paper
• The role of CB1 receptors in psychostimulant addiction

  2008cited by this paper
• Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.

  2008cited by this paper
• The Novel Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Suppresses Food Intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats

  2008cited by this paper
• Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist Rimonabant

  2008cited by this paper
• Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A).

  2008cited by this paper
• A neutral CB1 receptor antagonist reduces weight gain in rat.

  2007cited by this paper
• Previous Exposure to THC Alters the Reinforcing Efficacy and Anxiety-Related Effects of Cocaine in Rats

  2007cited by this paper
• Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.

  2007cited by this paper
• Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

  2006cited by this paper
• Cannabinoid CB1 Receptor Antagonist AM251 Inhibits Cocaine-Primed Relapse in Rats: Role of Glutamate in the Nucleus Accumbens

  2006cited by this paper
• Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

  2006cited by this paper
• Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.

  2006cited by this paper
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

  2005cited by this paper
• The Endogenous Cannabinoid Anandamide and Its Synthetic Analog R(+)-Methanandamide Are Intravenously Self-Administered by Squirrel Monkeys

  2005cited by this paper
• Cannabinoid CB1 receptors control conditioned drug seeking.

  2005cited by this paper
• Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats

  2005cited by this paper
• Nicotine induces conditioned place preferences over a large range of doses in rats

  2005cited by this paper
• CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid‐seeking behaviour in the rat

  2004cited by this paper
• Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences

  2004cited by this paper
• The validity of the reinstatement model of craving and relapse to drug use

  2003cited by this paper
• Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.

  2002cited by this paper
• SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

  2002cited by this paper
• A cannabinoid mechanism in relapse to cocaine seeking

  2001cited by this paper
• Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys

  2000cited by this paper
• CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats.

  1999cited by this paper
• Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition

  1997cited by this paper
• SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.

  1997cited by this paper
• Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

  1997cited by this paper
• Nicotine as a reinforcer in human subjects and laboratory animals.

  1983cited by this paper
• Persistent behavior at high rates maintained by intravenous self-administration of nicotine.

  1981cited by this paper
• Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey.

  1973cited by this paper

• Chemical Probes for Investigating the Endocannabinoid System.

  2025cites this paper
• Advancing Preclinical Models for Medications Development for Cannabis Use Disorder: Self-Administration and Beyond

  2025cites this paper
• Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.

  2025cites this paper
• Advances in the study of pharmacotherapy for addiction to naturally-derived psychoactive substances.

  2025cites this paper
• The influence of stress and social defeat on neurobiological reinforcement mechanisms across reward to withdrawal in nicotine addiction

  2025cites this paper
• PHARMACOLOGICAL CHARACTERIZATION OF A NEW SYNTHESIS COMPOUND WITH ANTAGONISTIC ACTION ON CB1 RECEPTORS: EVIDENCE FROM THE ANIMAL EXPERIMENTAL MODEL.

  2025cites this paper
• Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years

  2025cites this paper
• Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.

  2025cites this paper
• Neurobiology of Stress-Induced Nicotine Relapse

  2024cites this paper
• Cannabis use disorder: from neurobiology to treatment

  2024cites this paper
• Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action

  2024cites this paper
• A Study on the Drug Abuse and Crimes Impacts on Youth

  2024cites this paper
• AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects

  2024cites this paper
• Adult consequences of repeated nicotine and Δ9-tetrahydrocannabinol (THC) vapor inhalation in adolescent rats

  2024cites this paper
• Differential disruption of response alternation by precipitated Δ9-THC withdrawal and subsequent Δ9-THC abstinence in mice.

  2024cites this paper
• Decreased Ventral Tegmental Area CB1R Signaling Reduces Sign Tracking and Shifts Cue–Outcome Dynamics in Rat Nucleus Accumbens

  2023cites this paper
• Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

  2023cites this paper
• Genetic variation in fatty acid amide hydrolase (FAAH): Associations with early drinking and smoking behaviors.

  2022cites this paper
• Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge

  2022cites this paper
• Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review

  2022cites this paper
• Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist/inverse agonist rimonabant on fentanyl discrimination in male rats.

  2022cites this paper
• Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research

  2022cites this paper
• Significant association of nicotine reinforcement and cue reactivity: a translational study in humans and rats

  2021cites this paper
• New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence

  2021cites this paper
• Mitragynine (Kratom)-Induced Cognitive Impairments in Mice Resemble Δ9-THC and Morphine Effects: Reversal by Cannabinoid CB1 Receptor Antagonism

  2021cites this paper
• CB1 Receptor Neutral Antagonist Treatment Epigenetically Increases Neuropeptide Y Expression and Decreases Alcohol Drinking.

  2021cites this paper
• Untapped endocannabinoid pharmacological targets: pipe dream or pipeline?

  2021cites this paper
• Cannabis use and cannabis use disorder

  2021cites this paper
• Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates

  2020influential citation
• Neural Substrates and Circuits of Drug Addiction.

  2020cites this paper
• Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation

  2020cites this paper
• Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement.

  2020cites this paper
• Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder

  2020cites this paper
• A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity.

  2019cites this paper
• Nicotine Reward and Abstinence: Role of the CB1 Receptors

  2019cites this paper
• Vaporized Cannabis Extracts Have Reinforcing Properties and Support Conditioned Drug-Seeking Behavior in Rats

  2019cites this paper
• The endocannabinoid system: from the receptors to therapy

  2019cites this paper
• Psychosocial and Pharmacological Interventions for the Treatment of Cannabis Use Disorder.

  2019cites this paper
• Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders

  2019cites this paper
• Probing the CB1 Cannabinoid Receptor Binding Pocket with AM6538, a High-Affinity Irreversible Antagonist

  2019cites this paper
• Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development.

  2019cites this paper
• Medications development for food-based and drug use disorders.

  2019cites this paper
• Probing the CB1 cannabinoid receptor binding pocket with AM6538, a high-affinity irreversible antagonist.

  2019cites this paper
• Psychosocial and pharmacological interventions for the treatment of cannabis use disorder

  2018cites this paper
• Cannabinoid‐1 receptor neutral antagonist reduces binge‐like alcohol consumption and alcohol‐induced accumbal dopaminergic signaling

  2018cites this paper
• The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders

  2018cites this paper
• Animal Models of Cannabis Use Disorder

  2018cites this paper
• Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure

  2018cites this paper
• Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse

  2018cites this paper
• The role of (E)-6-chloro-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-styrylquinazolin-4(3H)-one in the modulation of cannabinoidergic system. A pilot study

  2018cites this paper
• Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies

  2018cites this paper
• Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats

  2018cites this paper
• When and How to Treat Possible Cannabis Use Disorder.

  2018cites this paper
• Epigenetic mechanisms associated with addiction-related behavioural effects of nicotine and/or cocaine: implication of the endocannabinoid system

  2017cites this paper
• Methylphenidate modifies the motion of the circadian clock Lamotrigine in mood disorders and cocaine dependence Cortical glutamate in postpartum depression Preclinical Studies of Cannabinoid Reward , Treatments for Cannabis Use Disorder , and Addiction-Related Effects of Cannabinoid Exposure

  2017influential citation
• Medications for substance use disorders (SUD): emerging approaches

  2017cites this paper
• Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation.

  2017influential citation
• The endocannabinoid system as a target for addiction treatment: Trials and tribulations

  2017cites this paper
• Analysis of natural product regulation of opioid receptors in the treatment of human disease.

  2017cites this paper
• Analysis of natural product regulation of cannabinoid receptors in the treatment of human disease.

  2017cites this paper
• Crystal Structure of the Human Cannabinoid Receptor CB1.

  2016cites this paper
• Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats

  2016cites this paper
• Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research

  2016cites this paper
• Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?

  2016cites this paper
• Discovery of (E)-3-(4-(Diethylamino) phenyl)-1-phenyl-2-phenylsulfonyl)prop-2-en-1-one as Novel Cannabinoid Receptor 2 Ligands

  2016cites this paper